This study aimed to elucidate the anti-remodeling effects of empagliflozin (EMPA) in the presence of post-MI left ventricular systolic dysfunction, the interplay with diabetes status and the myocardial mechanisms underlying, by evaluating the involvement of GCH1 and the NOS pathway. The gene discussed is NOS1; the disease is diabetes mellitus.